{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:19:27Z","timestamp":1790965167862,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T00:00:00Z","timestamp":1547078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T00:00:00Z","timestamp":1547078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The 2013\u20132016 Ebola virus (EBOV) disease epidemic demonstrated the grave consequences of filovirus epidemics in the absence of effective therapeutics. Besides EBOV, two additional ebolaviruses, Sudan (SUDV) and Bundibugyo (BDBV) viruses, as well as multiple variants of Marburg virus (MARV), have also caused high fatality epidemics. Current experimental EBOV monoclonal antibodies (mAbs) are ineffective against SUDV, BDBV, or MARV. Here, we report that a cocktail of two broadly neutralizing ebolavirus mAbs, FVM04 and CA45, protects nonhuman primates (NHPs) against EBOV and SUDV infection when delivered four days post infection. This cocktail when supplemented by the anti-MARV mAb MR191 exhibited 100% efficacy in MARV-infected NHPs. These findings provide a solid foundation for clinical development of broadly protective immunotherapeutics for use in future filovirus epidemics.<\/jats:p>","DOI":"10.1038\/s41467-018-08040-w","type":"journal-article","created":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T05:23:09Z","timestamp":1546579389000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Post-exposure immunotherapy for two ebolaviruses and Marburg virus in nonhuman primates"],"prefix":"10.1038","volume":"10","author":[{"given":"Jennifer M.","family":"Brannan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihua","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3110-7022","authenticated-orcid":false,"given":"Katie A.","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura I.","family":"Prugar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Shulenin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Kailasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henna","family":"Raina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Niaz","family":"Rahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logan","family":"Banadyga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Tierney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2964-3184","authenticated-orcid":false,"given":"Xuelian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick W.","family":"Holtsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Dye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangguo","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Javad","family":"Aman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,10]]},"reference":[{"key":"8040_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jhin.2015.01.002","volume":"90","author":"P Shears","year":"2015","unstructured":"Shears, P. & O\u2019Dempsey, T. J. Ebola virus disease in Africa: epidemiology and nosocomial transmission. J. Hosp. Infect. 90, 1\u20139 (2015).","journal-title":"J. Hosp. Infect."},{"key":"8040_CR2","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nri1154","volume":"3","author":"H Feldmann","year":"2003","unstructured":"Feldmann, H., Jones, S., Klenk, H. D. & Schnittler, H. J. Ebola virus: from discovery to vaccine. Nat. Rev. Immunol. 3, 677\u2013685 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"8040_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nature14594","volume":"524","author":"MW Carroll","year":"2015","unstructured":"Carroll, M. W. et al. Temporal and spatial analysis of the 2014\u20132015 Ebola virus outbreak in West Africa. Nature 524, 97\u2013101 (2015).","journal-title":"Nature"},{"key":"8040_CR4","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.cell.2016.10.014","volume":"167","author":"WE Diehl","year":"2016","unstructured":"Diehl, W. E. et al. Ebola virus glycoprotein with increased infectivity dominated the 2013\u20132016 epidemic. Cell 167, 1088\u20131098 e1086 (2016).","journal-title":"Cell"},{"key":"8040_CR5","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.cell.2015.06.007","volume":"161","author":"DJ Park","year":"2015","unstructured":"Park, D. J. et al. Ebola virus epidemiology, transmission, and evolution during seven months in Sierra Leone. Cell 161, 1516\u20131526 (2015).","journal-title":"Cell"},{"key":"8040_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/srep20514","volume":"6","author":"W Furuyama","year":"2016","unstructured":"Furuyama, W. et al. Discovery of an antibody for pan-ebolavirus therapy. Sci. Rep. 6, 20514 (2016).","journal-title":"Sci. Rep."},{"key":"8040_CR7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.celrep.2017.03.049","volume":"19","author":"KA Howell","year":"2017","unstructured":"Howell, K. A. et al. Cooperativity enables non-neutralizing antibodies to neutralize Ebola virus. Cell Rep. 19, 413\u2013424 (2017).","journal-title":"Cell Rep."},{"key":"8040_CR8","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.celrep.2016.04.026","volume":"15","author":"KA Howell","year":"2016","unstructured":"Howell, K. A. et al. Antibody treatment of Ebola and Sudan virus infection via a uniquely exposed epitope within the glycoprotein receptor-binding site. Cell Rep. 15, 1514\u20131526 (2016).","journal-title":"Cell Rep."},{"key":"8040_CR9","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.cell.2017.04.037","volume":"169","author":"AZ Wec","year":"2017","unstructured":"Wec, A. Z. et al. Antibodies from a human survivor define sites of vulnerability for broad protection against ebolaviruses. Cell 169, 878\u2013890 e815 (2017).","journal-title":"Cell"},{"key":"8040_CR10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1126\/science.aag3267","volume":"354","author":"AZ Wec","year":"2016","unstructured":"Wec, A. Z. et al. A \u201cTrojan horse\u201d bispecific-antibody strategy for broad protection against ebolaviruses. Science 354, 350\u2013354 (2016).","journal-title":"Science"},{"key":"8040_CR11","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.cell.2017.04.038","volume":"169","author":"X Zhao","year":"2017","unstructured":"Zhao, X. et al. Immunization-elicited broadly protective antibody reveals Ebola virus fusion loop as a site of vulnerability. Cell 169, 891\u2013904 e815 (2017).","journal-title":"Cell"},{"key":"8040_CR12","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s41564-018-0157-z","volume":"3","author":"AI Flyak","year":"2018","unstructured":"Flyak, A. I. et al. Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region. Nat. Microbiol 3, 670\u2013677 (2018).","journal-title":"Nat. Microbiol"},{"key":"8040_CR13","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.cell.2015.12.022","volume":"164","author":"AI Flyak","year":"2016","unstructured":"Flyak, A. I. et al. Cross-reactive and potent neutralizing antibody responses in human survivors of natural Ebola virus infection. Cell 164, 392\u2013405 (2016).","journal-title":"Cell"},{"key":"8040_CR14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.immuni.2018.06.018","volume":"49","author":"P Gilchuk","year":"2018","unstructured":"Gilchuk, P. et al. Multifunctional Pan-ebolavirus antibody recognizes a site of broad vulnerability on the Ebola virus glycoprotein. Immunity 49, 363\u2013374 e310 (2018).","journal-title":"Immunity"},{"key":"8040_CR15","doi-asserted-by":"publisher","first-page":"e02154","DOI":"10.1128\/mBio.02154-15","volume":"7","author":"ZA Bornholdt","year":"2016","unstructured":"Bornholdt, Z. A. et al. Host-primed Ebola virus GP exposes a hydrophobic NPC1 receptor-binding pocket, revealing a target for broadly neutralizing antibodies. MBio 7, e02154\u201302115 (2016).","journal-title":"MBio"},{"key":"8040_CR16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.coviro.2012.02.015","volume":"2","author":"EH Miller","year":"2012","unstructured":"Miller, E. H. & Chandran, K. Filovirus entry into cells\u2014new insights. Curr. Opin. Virol. 2, 206\u2013214 (2012).","journal-title":"Curr. Opin. Virol."},{"key":"8040_CR17","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.cell.2015.12.044","volume":"164","author":"H Wang","year":"2016","unstructured":"Wang, H. et al. Ebola viral glycoprotein bound to its endosomal receptor Niemann\u2013Pick C1. Cell 164, 258\u2013268 (2016).","journal-title":"Cell"},{"key":"8040_CR18","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nature10348","volume":"477","author":"JE Carette","year":"2011","unstructured":"Carette, J. E. et al. Ebola virus entry requires the cholesterol transporter Niemann\u2013Pick C1. Nature 477, 340\u2013343 (2011).","journal-title":"Nature"},{"key":"8040_CR19","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1126\/science.1110656","volume":"308","author":"K Chandran","year":"2005","unstructured":"Chandran, K., Sullivan, N. J., Felbor, U., Whelan, S. P. & Cunningham, J. M. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308, 1643\u20131645 (2005).","journal-title":"Science"},{"key":"8040_CR20","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/nature10380","volume":"477","author":"M Cote","year":"2011","unstructured":"Cote, M. et al. Small molecule inhibitors reveal Niemann\u2013Pick C1 is essential for Ebola virus infection. Nature 477, 344\u2013348 (2011).","journal-title":"Nature"},{"key":"8040_CR21","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1128\/JVI.02172-15","volume":"90","author":"ZY Keck","year":"2015","unstructured":"Keck, Z. Y. et al. Macaque monoclonal antibodies targeting novel conserved epitopes within filovirus glycoprotein. J. Virol. 90, 279\u2013291 (2015).","journal-title":"J. Virol."},{"key":"8040_CR22","doi-asserted-by":"crossref","unstructured":"Warfield, K. L. et al. Role of antibodies in protection against Ebola virus in nonhuman primates immunized with three vaccine platforms. J. Infect. Dis.\u00a0218, S553\u2013S564 (2018).","DOI":"10.1093\/infdis\/jiy316"},{"key":"8040_CR23","doi-asserted-by":"publisher","first-page":"10982","DOI":"10.1128\/JVI.01490-15","volume":"89","author":"E Davidson","year":"2015","unstructured":"Davidson, E. et al. Mechanism of binding to Ebola virus glycoprotein by the ZMapp, ZMAb, and MB-003 cocktail antibodies. J. Virol. 89, 10982\u201310992 (2015).","journal-title":"J. Virol."},{"key":"8040_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-3527(08)60733-2","volume":"47","author":"H Feldmann","year":"1996","unstructured":"Feldmann, H. & Klenk, H. D. Marburg and Ebola viruses. Adv. Virus Res 47, 1\u201352 (1996).","journal-title":"Adv. Virus Res"},{"key":"8040_CR25","doi-asserted-by":"publisher","first-page":"e1005016","DOI":"10.1371\/journal.ppat.1005016","volume":"11","author":"ML Fusco","year":"2015","unstructured":"Fusco, M. L. et al. Protective mAbs and cross-reactive mAbs raised by immunization with engineered Marburg virus GPs. PLoS Pathog. 11, e1005016 (2015).","journal-title":"PLoS Pathog."},{"key":"8040_CR26","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1128\/JVI.02171-15","volume":"90","author":"FW Holtsberg","year":"2015","unstructured":"Holtsberg, F. W. et al. Pan-ebolavirus and Pan-filovirus mouse monoclonal antibodies: protection against Ebola and Sudan viruses. J. Virol. 90, 266\u2013278 (2015).","journal-title":"J. Virol."},{"key":"8040_CR27","doi-asserted-by":"crossref","unstructured":"Mire, C. E. et al. Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. Sci Transl Med 9, eaai8711 (2017).","DOI":"10.1126\/scitranslmed.aai8711"},{"key":"8040_CR28","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.cell.2015.01.031","volume":"160","author":"AI Flyak","year":"2015","unstructured":"Flyak, A. I. et al. Mechanism of human antibody-mediated neutralization of Marburg virus. Cell 160, 893\u2013903 (2015).","journal-title":"Cell"},{"key":"8040_CR29","doi-asserted-by":"publisher","first-page":"142ra196","DOI":"10.1126\/scitranslmed.3003752","volume":"4","author":"C Sundling","year":"2012","unstructured":"Sundling, C. et al. High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site. Sci. Transl. Med. 4, 142ra196 (2012).","journal-title":"Sci. Transl. Med."},{"key":"8040_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature13777","volume":"514","author":"X Qiu","year":"2014","unstructured":"Qiu, X. et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514, 47\u201353 (2014).","journal-title":"Nature"},{"key":"8040_CR31","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/jcm.13.4.791-793.1981","volume":"13","author":"JB Moe","year":"1981","unstructured":"Moe, J. B., Lambert, R. D. & Lupton, H. W. Plaque assay for Ebola virus. J. Clin. Microbiol. 13, 791\u2013793 (1981).","journal-title":"J. Clin. Microbiol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-08040-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-08040-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-08040-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T13:57:27Z","timestamp":1671199047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-08040-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,10]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["8040"],"URL":"https:\/\/doi.org\/10.1038\/s41467-018-08040-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,10]]},"assertion":[{"value":"17 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.J.A. has stocks and S.S., H.V., and F.W.H. have stock options in Integrated Biotherapeutics, a company developing antibody therapeutics for Ebola virus disease. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"105"}}